Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Big truths, small spaces

The dragonfly teaches us something about commercial excellence

- PMLiVE

Johnson & Johnson’s Rybrevant granted FDA approval for lung cancer indications

The drug was previously authorised for use by the US regulator under the accelerated approval pathway

- PMLiVE

AbbVie gains rights to OSE’s chronic inflammation therapy in deal worth $713m

The company will gain an exclusive global license to develop, manufacture and commercialise OSE-230

- PMLiVE

BMS shares positive long-term results for Zeposia in relapsing multiple sclerosis

Zeposia is already approved in major markets for relapsing MS and ulcerative colitis

- PMLiVE

New genetic risk tool could predict multiple sclerosis in young adults much earlier

Approximately 2.8 million people worldwide are affected by the disabling neurological disease

- PMLiVE

Publicis Health UK promotes Katie McMorran and Clare Middleton as Langland group managing directors

McMorran will lead the agency's advertising practice and Middleton will head the clinical trial experience, medical strategy and education, and public relations disciplines

- PMLiVE

Women in pharma

With February marking the International Day of Women and Girls in Science, Iona Everson from PMGroup spoke to Emma Banks, CEO of ramarketing, to find out more about her career

- PMLiVE

UKRI appoints iiCON to deliver £1.5m initiative to tackle infection transmission

The project will aim to accelerate solutions that leverage technologies such as AI and novel diagnostics

- PMLiVE

FDA awards Orphan Drug Designation to SynaptixBio for rare brain disease therapy

Isolated hypomyelination is a form of TUBB4A leukodystrophy that has been identified relatively recently

- PMLiVE

Sanofi presents positive results for rilzabrutinib in chronic spontaneous urticaria

Phase 3 development of the treatment is expected to commence later this year

- PMLiVE

Radboud researchers use new method to improve diagnosis of rare diseases

Approximately 7,000 rare diseases collectively impact up to 5.9% of the global population

- PMLiVE

Shaping up for launch in ’24: three areas to explore for pharma

By Oli Hudson

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links